Previous News Releases
Turku – Finland, December 20, 2013. Faron announced today that it has received advise from the European Medicine Agency (EMA) for the clinical development plans of the FP-1201-lyo. According to the written advise, the EMA agreed to a large extent with proposed questions presented to the Agency. Faron had requested scientific advise for the pivotal pan-European clinical program to treat the acute respiratory distress syndrome (ARDS) with the intravenous recombinant human interferon beta-1a (FP-1201-lyo).
New data from the ALI/ARDS FPCLI001 study presented at the 2013 European Respiratory Society meeting.
Faron Pharmaceuticals Ltd. ("Faron") announced today that significant amount of new data was presented at the annual European Respiratory Society (ERS) meeting in Barcelona. The invited lecture was given by prof. Sirpa Jalkanen (University of Turku, Finland) during the lunch session organized jointly by the ERS and the New England Journal Medicine. The topic of the session was “Novel Strategies for Ventilating Patients with ARDS”. The FPCLI001 study details can be found from www.clinicaltrials.gov with NCT00789685 number.
Faron Pharmaceuticals Ltd. ("Faron") announced today that European Commission has granted €6 million from the seventh framework program (FP7) to support the FP-1201-lyo clinical phase III program (“Traumakine”), focusing to develop a first pharmacological treatment for acute respiratory distress syndrome (ARDS). Faron was informed about the positive evaluation of the application in May 2012. Following finishing all technical issues, the grant agreement has now been signed. The Consortium consists of the European Commission as a granting Agency, Faron Pharmaceuticals as a Coordinator and three other participating Partners of the Traumakine program, University College London Hospital (UCLH), University of Torino and University of Turku.
Faron Pharmaceuticals, Ltd. announced today that it was granted the final Young Innovative Company (YIC) period by the Finnish Funding Agency for Technology and Innovation (Tekes). This €375.000 grant is the final part of the one million euro YIC program. The main target of this grant has been and is to support commercialization of the Company’s lead program – Traumakine or FP-1201 for the treatment of acute lung injuries.
New data from the ALI/ARDS FPCLI001 study presented at the 2012 American Thoracic Society meeting: A 75% lower mortality in the FP-1201 treated group.
Faron Pharmaceuticals Ltd. ("Faron") announced today that the FPCLI001 Study Group has presented new data from the phase I/II clinical trial in acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) at the 2012 American Thoracic Society (ATS) meeting in San Francisco, USA. The trial was performed during 2009-2011 by eight UK based ICU sites and tested safety, tolerability and initial efficacy of FP-1201 on ALI/ARDS patients. The details of the study can be found from www.clinicaltrials.gov with NCT00789685 number.